Rabbit Recombinant Monoclonal Mu Opioid Receptor antibody. C-terminal. Suitable for WB and reacts with Transfected cell lysate, Recombinant fragment samples. Cited in 41 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA
Flow Cyt | WB | |
---|---|---|
Mouse | Not recommended | Predicted |
Rat | Not recommended | Predicted |
Recombinant fragment | Not recommended | Expected |
Transfected cell lysate | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment | Dilution info - | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Species Mouse | Dilution info - | Notes - |
Species Rat | Dilution info - | Notes - |
Species Transfected cell lysate | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell lysate | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity). Isoform 12. Couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity. Isoform 17. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.
MOR1, OPRM1, Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP
Rabbit Recombinant Monoclonal Mu Opioid Receptor antibody. C-terminal. Suitable for WB and reacts with Transfected cell lysate, Recombinant fragment samples. Cited in 41 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA
The antibody detects the band of interest in transfected cell lines. When tested in our lab, we were not able to detect any signal from the endogenous protein.
This antibody can be used in IHC and ICC/IF as demonstrated in several publications, however, it did not pass our internal validation in these applications. Please refer to PMID 20851148, 21957251, 26290245, and other references.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The Mu Opioid Receptor also known as MOR mu receptor or mu opiate receptor represents an important protein involved in pain and reward mechanisms. It is a G-protein coupled receptor with a mass of approximately 45 kDa. This receptor shows broad expression in the central nervous system with significant presence in areas such as the brainstem thalamus and spinal cord. MORs have a high affinity for endogenous opioids such as endorphins as well as exogenous opioid drugs like morphine.
The Mu Opioid Receptor plays an essential role in modulating pain perception and response to opioids. It interacts predominantly with inhibitory G-proteins reducing neuronal excitability by decreasing cAMP levels and increasing potassium ion conductance. MORs are part of opioid receptor family which also includes delta and kappa receptors forming a complex regulatory system for the opioid signaling pathways. These receptors also modulate the release of neurotransmitters like GABA and dopamine.
Signaling through the Mu Opioid Receptor integrates with the analgesic and reward pathways. It is important in the pain modulation pathway where it influences the perception of and response to pain stimuli. MORs interact with proteins such as adenylate cyclase and beta-arrestin which mediate desensitization and down-regulation processes. This interaction can also modulate the activity of dopamine pathways further linking MOR to reward and addiction mechanisms.
The Mu Opioid Receptor is closely connected to conditions like addiction and chronic pain. Anomalies in MOR function or expression can lead to an increased risk of opioid addiction due to its pivotal role in the reward pathway. Additionally chronic pain conditions might involve altered MOR signaling or density impacting pain management. Understanding MOR interactions with proteins like dopamine receptors can provide deeper insights into Huntington’s disease and the role of opioid receptors in its pathology.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) at 1/1000 dilution
Lane 1: Mu Opioid Receptor transfected HEK-293 (Human epithelial cell line from embryonic kidney) lysate at 10 µg
Lane 2: HEK-293T cell lysate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 45 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com